Navigation path

Key Research Areas

HIV/AIDS

Since the start of the epidemic the European Commission has considered HIV/AIDS as a top priority and has significantly invested in HIV/AIDS research. Under the Millennium Development Goals the European Commission has further strengthened its efforts to work with the global community to combat HIV/AIDS and significant progress has been made so far. Thanks to effective treatments, HIV is no longer a death sentence. Nevertheless, a number of challenges remain. The lack of an effective vaccine or cure, the emerging of resistance to existing drugs, complications in the course of the infection because of long-term treatment, co-infections and co-morbidities are among these challenges which require innovative solutions and long-term commitments. With its investment in research and innovation for HIV/AIDS, the European Commission is increasing the chances for the community to provide solutions to the challenges while fully exploiting the European Scientific excellence and enhancing European competitiveness.

 

HIV/AIDS research under Horizon 2020

HIV/AIDS research continues to be supported under Horizon 2020. During the first two years of the programme a total EC contribution of €75.57m has been committed. Of this, about 80% of the funds comes from the Societal Challenge: Health, Demographic Change and Wellbeing, (ref chart pie below) and includes €45 million on two large platforms for the development of a preventive or therapeutic vaccine as well as a €10m loan from the InnovFin ID instrument to develop a high-throughput HIV viral load test and 4 EDCTP2 grants.


HIV/AIDS research funding on H2020 (as of February 2016)

HIV/AIDS research under FP7

During the 7th Framework Programme for Research (FP7-2007-2013), over €175m was invested by the EU, of which €135m to support 28 collaborative research and innovation projects to fight HIV/AIDS. These projects tackled basic understanding of the disease, product development, and clinical management. The outcome of this investment resulted in more than a dozen new drugs or vaccine candidates in pre- or early clinical development; the creation of a large network of different cohorts with data from over 350.000 HIV+ individuals, completion of studies for new drugs formulations for pediatric use and the generation of in-vitro and in-vivo models to study HIV latency and persistence. Many more results have been generated by FP7-funded projects (some of which are still ongoing and further results are expected in the near future), as well as hundreds of scientific publications and several patents files.